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BRCA1/BRCA2 germline mutations are associated with an increased breast/ovarian cancer risk. Offspring gender
ratios may be skewed against male births in BRCA1 mutation carriers. In addition, the lack of viable homozygous
BRCA1/BRCA2-mutation carriers implies that recurrent miscarriages may be associated with homozygous fetuses.
Jewish Israeli high-risk women who were tested for being carriers of the predominant BRCA1/BRCA2 mutations
in Jewish high-risk families were analyzed for the sex of offspring and the rate of spontaneous miscarriages. Overall,
817 women participated: 393 BRCA1/BRCA2-mutation carriers (229 with breast/ovarian cancer) and 424 high-
risk noncarriers (208 with breast/ovarian cancer). No differences between the male-to-female offspring ratios of
all study groups were noted. Among mutation carriers, the offspring male-to-female ratio was 0.97 (444:460), and
among mutation carriers with cancer it was 0.92 (262:284). Similarly, no offspring gender skewing was noted
among high-risk noncarriers, regardless of health status. The rates of three or more spontaneous miscarriages among
participants with at least one live birth were 4.37% (15/343) among mutation carriers and 3% (12/401) among
high-risk women (Pp not signiﬁcant). In conclusion, the offspring gender ratio is similar in high-risk Jewish families
and in the general population. The issue of the rate of recurrent miscarriages in high-risk Jewishwomen is unresolved.
Germlinemutations in two genes,BRCA1 (MIM113705)
and BRCA2 (MIM 600185), are estimated to account for
∼80% of all inherited breast and ovarian cancer and
!50% of familial site-speciﬁc breast cancer (Ford et al.
1994, 1998). In Jewish high-risk individuals of Ashkena-
zi (East European) decent, three predominant, seeming-
ly founder mutations—185delAG (BRCA1), 5382insC
(BRCA1), and 6174delT (BRCA2)—seem to account for
a substantial proportion (70%–85%) of germline mu-
tations detected in high-risk families with inherited
breast and ovarian cancer, including ∼40%–50% of
familes with site-speciﬁc breast cancer, and in2.5% of
the general Jewish Ashkenazi population (Berman et al.
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1996; Neuhausen et al. 1996, 1998; Roa et al. 1996;
Abeliovich et al. 1997; Szabo and King 1997). Notably,
other mutations in both BRCA1 and BRCA2 are infre-
quent among Jewish Ashkenazi women at a high risk
for cancer (Shiri-Sverdlov et al. 2000; Kauff et al. 2002).
The only well-established phenotype of heterozygous
BRCA1/BRCA2 mutation carriers is an increased risk
for breast, ovarian, and, to a lesser extent, other cancers
(e.g., pancreatic and prostate) (Ford et al. 1994; Struew-
ing et al. 1997; Breast Cancer Linkage Consortium
[BCLC] 1999; Thompson et al. 2002; see also BCLC
Web site). A recent report suggested that there is a skew-
ing of offspring gender ratios, favoring female offspring
in BRCA1 mutation carriers and not in BRCA2 muta-
tion carriers, an observation that seemingly supported
the role that BRCA1 protein plays in X chromosome
inactivation (de la Hoya et al. 2003). Another intriguing
fact is that no viable homozygous BRCA mutation car-
riers have been established in any species, including
human beings (Gowen et al. 1996; Suzuki et al. 1997;
Kuschel et al. 2001). On the basis of the carrier rate in
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the general population of the mutations predominant in
Jewish populations (0.9% for the 185delAG BRCA1
mutation and 1.5% for the 6174delTBRCA2mutation),
the predicted rate of fetuses born to Jewish Ashkenazim
being homozygous for one of these two mutations is
expected to be between 1 in 20,000 births for 6174delT
and 1 in 40,000 births for 185delAG. Taken together,
the fact that no homozygous mutation carrier has been
reported (Kuschel et al. 2001) and the lack of viable
homozygous mutation carriers in animal models (Gowen
et al. 1996; Suzuki et al. 1997) led us to hypothesize
that a plausible reason for recurrent spontaneous mis-
carriages among Jewish Ashkenazi women may be fetal
homozygosity for the recurring BRCA1/BRCA2 muta-
tions in this ethnic group.
The aim of this study was to assess the putative effect
of being a BRCA1/BRCA2 germline mutation carrier on
offspring gender ratio and on the rate of recurrent spon-
taneous miscarriages.
Jewish women who were counseled for breast/ovarian
cancer risk by the oncogenetics services at the Sheba
Medical Center in Tel-Hashomer or at the Institute of
Genetics at Rambam Medical Center from January 1,
1999, until December 31, 2002, were eligible. Exclusion
criteria were non-Jewish origin and unwillingness to par-
ticipate. The study participants were subdivided into
mutation carriers and noncarriers, and each group was
further subdivided into affected (with breast/ovarian
cancer) or unaffected.
The study was approved by the institutional review
board of both medical centers, and each participant
signed a written informed consent. Data regarding off-
spring gender and reproductive history, along with de-
tailed personal and family history of cancer and de-
mographic data, were collected routinely at counseling.
Ethnic origin was ascertained for at least three prior
generations, on the basis of the countries of birth of the
parents and grandparents. On the basis of personal and
family cancer history, “high risk” status was assigned to
(1) women who have at least two ﬁrst-degree relatives
with breast cancer, one of whom was diagnosed at !40
years of age, (2) women who have at least one ﬁrst-
degree relative who had ovarian cancer at any age and
at least one ﬁrst-degree relative with breast cancer, and
(3) women who have at least two ﬁrst-degree relatives
with breast cancer at any age, one of whom had bilateral
breast cancer.
DNA was extracted from peripheral venous leuko-
cytes by use of the PUREGene DNA extraction kit
(Gentra Inc.), in accordance with the manufacturer’s
recommended protocol. Three predominant Jewish mu-
tations were tested: 185delAG and 5382insC in BRCA1
and 6174delT in BRCA2. Mutation analysis schemes
were based on PCR and restriction enzyme digests that
distinguish the wild type from the mutant allele, as de-
scribed elsewhere (Rohlfs et al. 1997).
Categorical variables were compared with the use of
x2 tests, and continuous variables were compared using
t-tests, adjusting for the effect of birth cohort when nec-
essary. All statistical analyses were performed using S-
Plus (S-Plus 2000 Professional Release 3, Insightful
Corp.).
Overall, 817 women participated in this study, and
393 were carriers of one of the predominant Jewish
mutations in BRCA1 (185delAG, ; 5382InsC,np 195
) or in BRCA2 (6174delT, ). Of the 393np 69 np 129
carriers, 169 were diagnosed with breast cancer, 47 with
ovarian cancer, and 13 with both cancer types. Of the
424 noncarriers, 192 were diagnosed with breast cancer,
13 with ovarian cancer, and 4 with both cancer types.
Study participants represent 82.6% of the total 989
women who were eligible for this study.
In both mutation carriers and noncarriers, the mean
age of unaffected women was signiﬁcantly younger than
the mean age of women diagnosed with cancer ( )Pp 0
(table 1). The mean age at counseling in the noncarrier
group was signiﬁcantly older than that of the carriers
( ) (table 1). Yet, the mean age at counselingPp .0001
in all groups ranged from 44.4 to 53.6 years, which are
considered to be ages at which the reproductive cycle
has been completed. The mean age at diagnosis of breast
cancer was 43.28.9 years for carriers and 48.89.8
years for noncarriers ( ); the mean age at diagnosisPp 0
of ovarian cancer was 51.411.0 years for carriers and
57.59.4 years for noncarriers ( ). The majorityPp .04
of study participants (97.3%), including both carriers
and noncarriers, were of Ashkenazi origin, and the rest
were of Iraqi origin, of Balkan origin, or born in Israel.
Of the study participants, 91% of the mutation car-
riers and 95% of the noncarriers gave birth at least once.
A statistically signiﬁcant difference in the mean number
of children was noted between carriers (2.33  1.24)
and noncarriers (2.511.3) ( ). No signiﬁcantPp .045
differences in the distribution of the number of children
were noted between affected and unaffected women
within each group.
The total number of males born to noncarriers was
542, compared with 522 females (rate ratio 1.038).
Among mutation carriers, there were 444 male off-
spring, compared with 460 female offspring (rate ratio
0.965). Analysis of offspring gender ratio by speciﬁc
mutation type shows that there were 215 boys and 219
girls (rate ratio 0.98) among 185delAG BRCA1 muta-
tion carriers, 71 boys and 84 girls (rate ratio 0.84)
among 5382InsC BRCA1 mutation carriers, and 158
boys and 157 girls (rate ratio 1.006) among 6174delT
BRCA2 mutation carriers. Combined analyses of all
BRCA1 carriers (185delAG and 5382InsC) showed that
there were 286 male and 303 female offspring (rate ratio
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0.943). The differences in rate ratios between all groups
(by speciﬁc mutation and by BRCA1 clustering) are sta-
tistically insigniﬁcant (table 1).
Of the study participants who had been pregnant at
some time in their life ( and amongnp 343 np 401
mutation carriers and noncarriers, respectively), 231 re-
ported having at least one spontaneous miscarriage: 113
(33%) of the carriers and 118 (30%) of the noncarriers
( ). In terms of unaffected women only, therePp .34
were 44 carriers (31%) and 64 noncarriers (33%) who
reported having at least one spontaneous miscarriage
( ). Among mutation carriers who had been preg-Pp .87
nant, 15 (4.37%) had three or more spontaneous mis-
carriages (2 unaffected women and 13 women with
breast/ovarian cancer, ), and, among noncarrierPp .11
women who had been pregnant, there were 12 women
(3%) with three or more spontaneous miscarriages,
evenly distributed among affected and unaffected indi-
viduals ( ). The mean number of spontaneousPp .5
abortions for women who had been pregnant was 0.41
 0.7 for unaffected mutation carriers and 0.50 0.95
for noncarriers ( ).Pp .8
Among mutation carriers, though the mean rate of
spontaneous miscarriages was higher among affected
women, compared with asymptomatic mutation carri-
ers, the difference was of borderline signiﬁcance statis-
tically ( ). However, these differences could notPp .079
be shown when stratiﬁcation for age at counseling was
performed.
In this study, no apparent differences in male-to-
female offspring ratio were noted in Jewish women who
are BRCA1 or BRCA2 mutation carriers, and the off-
spring gender ratio was within that reported for the gen-
eral Western world populations, 1.06 (Davis et al.
1998). In Israel, the male-to-female ratios were 1.059
(70,173:66,217) in 2000 and 1.045 (71,318:68,217) in
2002 (Central Bureau of Statistics 2001, 2003). In the
present study, for high-risk noncarriers, the ratios were
also within those of the general population, regardless
of disease status. Our data differ from those in a recent
report on Spanish BRCA1-mutation carriers: in that
study, a two-fold excess of female offspring was noted
in BRCA1 mutation carriers (de la Hoya et al. 2003).
Notably, among the Spanish mutation carriers, there
were three families who are carriers of the 185delAG
BRCA1 mutation. In these three families, the ratio of
male to female offspring was 0.533 (24:45). By contrast,
in the present study, which encompassed 195 185delAG-
mutation carriers, representing 174 independent fami-
lies, there were 215 boys and 219 girls—a male-to-
female ratio of 0.981. The reasons for the inconsistent
results in terms of the effect of BRCA1 mutation on
offspring gender ratio in both studies may be attributed
to several factors, and the difference in sample size may
be the single most important factor. Additionally, the
number of families analyzed herein is larger than the
number of families analyzed in the Spanish study, and,
therefore, our observations are independent of other
confounding familial variables. Alternatively, the precise
location of gene mutations may affect the resulting pro-
tein function, with respect to its putative role in X chro-
mosome inactivation. Another possibility is that there
are other genetic factors that control offspring gender
ratio in the Spanish population and are in association
with BRCA1 mutations (either genetically or function-
ally) but are nonexistent in the Jewish Ashkenazi pop-
ulation. The need to assess these factors in a larger study
is apparent.
No differences with regard to the rate of recurrent
spontaneous miscarriages among all study groups were
shown. However, the ﬁnding that the rate of recurrent
spontaneous miscarriages among all subsets of study
participants was higher than that reported for the av-
erage risk population (.8%–1%) (Stirrat 1990; Katz and
Kuller 1994; Bick et al. 1998) is intriguing, but should
be interpreted very cautiously. The often-quoted refer-
ence numbers for recurrent (3) miscarriages in the gen-
eral population (.8%–1%) are based on historical, non-
Israeli controls (Alberman 1988; Bick et al. 1998). In
addition, in the study by Roman et al. (1978), which
analyzes the data set that is most often cited, there were
no women who were pregnant 14 times, whereas, in the
present study, all but one of the women who had 3
spontaneous miscarriages were pregnant at least 5 times.
Thus, comparison of the literature-based historical data
on non-Jewish women with the current data is invalid.
However, given the biological plausibility that BRCA1/
BRCA2 proteins are involved in determining fetal out-
come (Gowen et al. 1996; Suzuki et al. 1997), the need
for a larger study that will compare spontaneous mis-
carriage rates among mutation carriers and high-risk
women with the rates among an ethnically matched,
average-risk population is obvious. This preliminary ob-
servation, if conﬁrmed, may signify that, in genetically
homogeneous populations with a limited repertoire of
mutations in BRCA1/BRCA2, the study of recurrent
miscarriages should include testing for germline muta-
tions in both genes, especially if there is a suggestive
family history.
The limitations of this study should be pointed out.
The study population was highly selected for a personal
and family history of breast/ovarian cancer. Therefore,
the carriers do not represent the total carrier population,
and the noncarriers do not represent the general Israeli
population. The effect of this inherent limitation on off-
spring gender ratio is minimal, in all likelihood, since
the results were compared within each group and with
valid reliable data derived from the Israeli population.
Another drawback of the study is the signiﬁcant age
differences among the four subsets of analyzed groups,
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though the mean ages of all groups were beyond the
reproductive period. Although the younger age of mu-
tation carriers, affected and unaffected, may result in a
lower number of live births, this fact by itself could not
have a signiﬁcant effect on offspring gender ratio.
We conclude that among Jewish women at high risk
for developing breast/ovarian cancer, either because of
family history or by virtue of being BRCA1/BRCA2mu-
tation carriers, there is no skewing of offspring gender
ratio. The issue of the rate of recurrent spontaneous
miscarriages among Jewish BRCA1/BRCA2 mutation
carriers and high-risk women is yet to be resolved by
analysis of an appropriate control group.
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